Valeant Pharmaceuticals Completes European Ops Sale

Aliso Viejo-based Valeant Pharmaceuticals said late Thursday that it has completed its sale of its European operations to Meda AB, in a deal worth approximately $425M in cash. Valeant had originally announced the deal August 4th. The deal included certain business operations located in Western Europe, Easter Europe, and other markets. Valeant said it was advised by Goldman, Sachs & Co. and Skadden, Arps, Slate, Meagher & Flom LLP in the deal.